Dupixent (dupilumab) and Adbry (tralokinumab) are FDA-approved biologic therapies for those with severe eczema that do not ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

The FDA is to review Sanofi/Regeneron's Dupixent as a treatment for asthma, a new use that could more than double its sales following its previous approval for eczema. Analysts predict peak annual ...

Sanofi’s Dupixent (dupilumab ... the first topical treatment specifically approved for chronic hand eczema (CHE).

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

Dyshidrotic eczema commonly causes small, itchy blisters. Treatment typically includes topical products and applying a cool compress. Dyshidrotic eczema, also known as dyshidrosis or pompholyx ...

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for priority review the supplemental biologics license application for ...

Biologic treatments are a new option for people ... might also prescribe these medicines off-label for other types of eczema. Dupixent and Adbry are “monoclonal antibodies.” ...

(Reuters) - Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback ...